AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Compass Therapeutics to Present at the 40th Cowen Health Care Conference

February 28, 2020 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 28, 2020--

Compass Therapeutics, a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a company overview at the 40 th Annual Cowen Health Care Conference in Boston on Tuesday, March 3, 2020.

Dr. Schuetz’s presentation will feature an update on the ongoing Phase 1 trial of the company’s lead candidate, CTX-471, a fully human agonistic antibody of CD137 being evaluated in patients with advanced solid tumors. Dr. Schuetz will also share the company’s progress on CTX-8371, a novel PD-1/PD-L1 bispecific, which has shown significantly increased activity in preclinical testing compared to PD-1 or PD-L1 monoclonal antibody therapies available commercially.

The presentation details are:

Date: Tuesday, March 3, 2020
Time: 11:00 – 11:25 a.m. ET
Location: Boston Marriott Copley Place

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. Compass is leveraging its proprietary StitchMabs™ and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200228005041/en/

CONTACT: Lisa Raffensperger

Ten Bridge Communications

lisa@tenbridgecommunications.com

617-903-8783

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Compass Therapeutics

Copyright Business Wire 2020.

PUB: 02/28/2020 08:00 AM/DISC: 02/28/2020 08:01 AM

http://www.businesswire.com/news/home/20200228005041/en